Duloxetine for stress urinary incontinence is marketed by Lilly under the brand name Yentreve.(R)
(1) Koponen, H., et al. Efficacy of Duloxetine for the Treatment of Generalized Anxiety Disorder: Implications for Primary Care Physicians. Prim Care Companion J Clin Psychiatry 2007: 9(2):100-107
(2) Rynn M., et al. Efficacy and Safety of Duloxetine in the Treatment of Generalized Anxiety Disorder: A Flexible-Dose, Progressive-Titration, Placebo- Controlled Trial. Depression and Anxiety 2007: 25(3): 182-189.
(3) Hartford, J., et al. Duloxetine as an SNRI Treatment for Generalized Anxiety Disorder: Results from a Placebo- and Active-Controlled Trial. Int Clin Psychopharmacol 2007: 22(3):167-74.
(4) Nicolini H, et al. Improvement of psychic and somatic symptoms in adult patients with generalized anxiety disorder: Examination from a duloxetine, venlafaxine extended-release, and placebo-controlled study. In Press at Psychological Medicine.
(5) Endicott, J., et al. Duloxetine Treatment for Role Functioning Improvement in Generalized Anxiety Disorder: Three Independent Studies. The Journal of Clinical Psychiatry 2007: 68(4):518-24
(6) Allgulander, C., et al. Pharmacotherapy of Generalized Anxiety Disorder: Results of Duloxetine Treatment from a Pooled Analysis of 3 Clinical Trials. Current Medical Research and Opinion 2007: 23(6): 1245-1252
(7) Davidson JRT, et al. Duloxetine treatment for relapse prevention in adults with generalized anxiety disorder: A 26- week randomized placebo-controlled study. Poster presented at the American College of Neuropsychopharmacology annual conference 2007. Boca Raton, Florida
(8) Lieb, R, et al. The epidemiology of generalised anxiety disorder in
|SOURCE Eli Lilly and Company|
Copyright©2008 PR Newswire.
All rights reserved